Upregulation of Nox4 by Hypertrophic Stimuli Promotes Apoptosis and Mitochondrial Dysfunction in Cardiac Myocytes

Tetsuro Ago, Junya Kuroda, Jayashree Pain, Cexiong Fu, Hong Li, Junichi Sadoshima

Rationale: NADPH oxidases are a major source of superoxide (O$_2^-$) in the cardiovascular system. The function of Nox4, a member of the Nox family of NADPH oxidases, in the heart is poorly understood.

Objective: The goal of this study was to elucidate the role of Nox4 in mediating oxidative stress and growth/death in the heart.

Methods and Results: Expression of Nox4 in the heart was increased in response to hypertrophic stimuli and aging. Neither transgenic mice with cardiac specific overexpression of Nox4 (Tg-Nox4) nor those with catalytically inactive Nox4 (Tg-Nox4-P437H) showed an obvious baseline cardiac phenotype at young ages. Tg-Nox4 gradually displayed decreased left ventricular (LV) function with enhanced O$_2^-$ production in the heart, which was accompanied by increased apoptosis and fibrosis at 13 to 14 months of age. On the other hand, the level of oxidative stress was attenuated in Tg-Nox4-P437H. Although the size of cardiac myocytes was significantly greater in Tg-Nox4 than in nontransgenic, the LV weight/tibial length was not significantly altered in Tg-Nox4 mice. Overexpression of Nox4 in cultured cardiac myocytes induced apoptotic cell death but not hypertrophy. Nox4 is primarily localized in mitochondria and upregulation of Nox4 enhanced both rotenone- and diphenyleneiodonium-sensitive O$_2^-$ production in mitochondria. Cysteine residues in mitochondrial proteins, including aconitase and NADH dehydrogenases, were oxidized and their activities decreased in Tg-Nox4.

Conclusions: Upregulation of Nox4 by hypertrophic stimuli and aging induces oxidative stress, apoptosis and LV dysfunction, in part because of mitochondrial insufficiency caused by increased O$_2^-$ production and consequent cysteine oxidation in mitochondrial proteins. (Circ Res. 2010;106:00-00.)

Key Words: reactive oxygen species ■ oxidative stress ■ superoxide ■ hypertrophy ■ apoptosis ■ aging

Reactive oxygen species (ROS), such as superoxide (O$_2^-$) and H$_2$O$_2$, play an important role in regulating cell growth and death of cardiac myocytes.$^1$-$^3$ In the heart under pathological conditions, mitochondria are the major source of ROS, which are generated primarily through electron leakage from the electron transport chain.$^4$ The leakage of electrons is a passive process caused by damage and/or downregulation of mitochondrial proteins, and does not appear to be tightly regulated.$^5$ ROS are also produced through O$_2^-$-producing enzymes, such as NADPH oxidases and xanthine oxidase. Although NADPH oxidases are the major source of O$_2^-$ production, their contribution to overall increases in ROS and myocardial responses under stress is not fully understood.

Thus far, seven members of the NADPH oxidase (Nox) family of proteins (Nox1 to Nox5 and Duox1 and 2) have been identified.$^6$-$^8$ All Nox proteins possess 6 membrane-spanning domains and a cytoplasmic region containing NAD(P)H- and FAD-binding domains in their C-terminal regions. Nox1, -2, -3 and -4 form a heterodimer with p22$^{phox}$, another catalytic core component of NADPH oxidases which stabilizes Nox proteins. Nox proteins accept electrons from either NADPH or NADH$^9$ and transfer them to molecular oxygen to generate O$_2^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^-$$^
Accumulating lines of evidence suggest that NADPH oxidases play an important role in mediating the development of cardiac hypertrophy and the progression of heart failure. For example, Nox2 mediates angiotensin II–induced cardiac hypertrophy. However, neither oxidative stress nor cardiac hypertrophy is suppressed in Nox2 knockout mice under pressure overload. On the other hand, expression of Nox4 is upregulated during cardiac hypertrophy induced by pressure overload. Thus, Nox4 may play an important role in mediating ROS generation and the development of cardiac hypertrophy and heart failure. However, the role of Nox4 in mediating cardiac hypertrophy and left ventricular dysfunction has not been clearly demonstrated because of a lack of an animal model in which the function of Nox4 in vivo can be elucidated in an isof orm specific manner.

Thus, the major goal in this investigation was to elucidate the function of Nox4 in the heart and in the cardiac myocytes therein. To this end, we have generated a specific anti-Nox4 antibody and transgenic (Tg) mouse models in which Nox4 in the heart is either stimulated or inhibited in an isof orm specific manner. In particular, we evaluated 1) how expression of Nox4 is regulated in response to hypertrophic stimuli and aging, 2) whether Nox4 affects growth and death of cardiac myocytes in the heart, and 3) subcellular localization of Nox4 and O$_2^-$ generation in cardiac myocytes.

**Methods**
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.

**Monoclonal Antibodies Against Nox4**
We made mouse monoclonal antibodies against Nox4 using a recombinant protein encoding the C-terminal cytoplasmic region of Nox4 (residues 307 to 578) tagged with His$_6$. We solubilized the recombinant Nox4 with 6 mol/L urea and injected it into mice after diluting it in PBS containing 0.6 mol/L urea. After screening more than 1000 clones by ELISA, we chose clones that detect the recombinant Nox4 protein used as an antigen, endogenous Nox4 in mouse tissues, including the heart and kidney (positive control), and endogenous Nox4 in neonatal rat cardiac myocytes by immunoblot. We found that some antibodies cross-react with Nox2. We selected antibodies which specifically react with Nox4, but not with Nox2.

**Tg Mice**
All Tg mice used in this study were generated on an FVB background with the α-myosin heavy chain promoter (courtesy of Dr J. Robbins). All protocols concerning the use of animals were approved by the Institutional Animal Care and Use Committee at the University of Medicine and Dentistry of New Jersey.

**Isotope-Coded Affinity Tag Labeling and Multidimensional Chromatography**
Isotope-coded affinity tag (ICAT) analysis was conducted as described previously.

**Statistical Analysis**
All values are expressed as means ± SEM. Statistical analyses between groups were performed by unpaired Student’s t test or 1-way ANOVA followed by a post hoc Fisher’s comparison test. A value of $P<0.05$ was accepted as significant.

**Results**
**Nox4 Is Expressed in Cardiac Myocytes and Is Upregulated by Hypertrophic Stimuli**
To characterize protein expression of Nox4 in the heart, we made Nox4 monoclonal antibodies, using the C-terminal cytoplasmic region of Nox4 as an antigen. Clone 3D2 was identified through ELISA and immunoblot analyses as a specific Nox4 antibody, which reacts with Nox4 but not with Nox2 (Figure 1A). Immunoblot analyses using the Nox4 antibody (3D2) confirmed that Nox4 is expressed in the mouse heart and in cultured neonatal rat cardiac myocytes. Expression of Nox4 in the mouse kidney, where Nox4 was originally identified, is shown as a positive control (Figure 1B).

We next examined the effects of hypertrophic stimuli on expression of Nox4 in the mouse heart. We treated mice with either angiotensin II (200 ng/kg/min) or phenylephrine (75 mg/kg per day), using osmotic pumps, or with transverse aortic constriction (TAC) for 14 days. Immunoblot analyses (Figure 1C) showed that Nox4 is upregulated 1.5-, 1.9-, and 3.4-fold by angiotensin II, phenylephrine, and TAC, respectively (all $P<0.05$ versus control). Immunostaining of mouse hearts with the anti-Nox4 antibody confirmed that myocardial expression of Nox4 is upregulated in hearts subjected to TAC (Figure 1D). Phenylephrine-induced upregulation of Nox4 was observed in myocyte-rich cultures but not in non–myocyte-rich cultures, suggesting that Nox4 upregulation occurs in cardiac myocytes (Online Figure I, A).

We also examined the effect of aging on Nox4 expression. Nox4 expression increased gradually between 3 and 12 months. Expression of p22$^{phox}$, a component of the NADPH oxidase complex known to associate with Nox4, was also increased with aging (Figure 1E). Staining with the anti-Nox4 antibody showed that upregula-
tion of Nox4 is diffusely observed in the myocardium, including in cardiac myocytes, in response to aging (Online Figure I, B).

Establishment of Tg Mice With Cardiac-Specific Overexpression of Nox4

To elucidate the functional consequence of Nox4 upregulation in the heart, we generated mice with cardiac-specific overexpression of wild-type Nox4 (Tg-Nox4) or a Nox4 mutant, in which proline 437 in the NADPH binding domain is substituted with a histidine residue (Tg-Nox4-P437H), using the \( \beta \)-myosin heavy chain promoter. Because a proline to histidine substitution in the NADPH binding domain in other Nox family proteins has been shown to abolish \( \text{O}_2^- \) production,\(^{18}\) we expect that the Nox4-P437H mutant is catalytically inactive. Furthermore, Nox4-P437H could function as a dominant negative against endogenous Nox4 by competing for interaction with p22phox.

We established Tg lines from 10 founders in Tg-Nox4 and 3 founders in Tg-Nox4-P437H. All of them were fertile, and expression levels of the transgenes were up to 4-fold higher than endogenous Nox4 in nontransgenic (NTg) mice (Figure 2A and data not shown). Tg expression of Nox4 or Nox4-P437H did not affect the level of Nox2 (Online Figure II, A). Although expression of antioxidant genes, such as manganese superoxide dismutase (MnSOD) and thioredoxin1, was not affected, catalase was modestly upregulated (1.7 fold) in Tg-Nox4 at 3 to 4 months of age (Online Figure II, D). None of the Tg-Nox4 or Tg-Nox4-P437H mice showed cardiac hypertrophy or abnormal LV function at baseline at 2 to 3 months of age (Online Figure II, B and C), although Tg-Nox4 mice had a tendency to show a slightly smaller LV weight/body weight (LVW/BW) (Online Figure I, B). Among the Tg mouse lines generated, we chose founders 3 (1.3-fold overexpression) and 13 (2.1-fold) in Tg-Nox4 and founders 11 (2.0-fold) and 14 (3.5-fold) in Tg-Nox4-P437H for further experiments.

Aged Tg-Nox4 Mice Display Decreased Cardiac Function Without Cardiac Hypertrophy

Although the cardiac phenotypes of young Tg-Nox4 and Tg-Nox4-P437H were not significantly different from NTg, Tg-Nox4 mice at the age of 13 to 14 months showed modestly but significantly increased LV end diastolic dimension and reduced LV ejection fraction (LVEF), an index of LV systolic function, compared to NTg and Tg-Nox4-P437H, as determined by echocardiographic measurement (Online Table I). Although LVW/BW at 13
to 14 months old in Tg-Nox4 was not significantly different from that in NTg or Tg-Nox4-P437H (Figure 2B), histological analyses showed that the LV cardiac myocyte cross-sectional area was significantly greater (Figure 2C; Online Figure III, A) in Tg-Nox4 than in NTg or Tg-Nox4-P437H mice. Cardiac fibrosis (Figure 2D; Online Figure IIB) and the number of TUNEL positive cells (Figure 2E; Online Figure III, C) were greater in Tg-Nox4 than in NTg and Tg-Nox4-P437H mice. The level of oxidative stress, including oxidative DNA damage and $O_2^{-}$, as evaluated by immunostaining of 8-hydroxyl-deoxyguanosine (8-OHdG) and dihydroethidium (DHE), respectively, was greater in Tg-Nox4 than in NTg and Tg-Nox4-P437H mice (Figure 3). Quantitative analysis showed that the intensity of DHE staining was significantly greater in Tg-Nox4 and significantly lower in Tg-Nox4-P437H, than in NTg (Figure 3B). These results suggest that increased expression of Nox4 enhances cardiac dysfunction and pathological changes in an age-dependent manner.

**Nox4 Stimulates Apoptosis but Not Hypertrophy in Cultured Cardiac Myocytes**

To evaluate the direct effect of Nox4 on growth and death, we overexpressed Nox4 in cardiac myocytes, using adenovirus transduction (Online Figure IV, A). Cell size was similar in control myocytes and Nox4-overexpressing myocytes, regardless of the multiplicity of infection (Figure 4A). Apoptotic cell death, as evaluated by TUNEL staining, was dose-dependently increased when Nox4 was overexpressed in cardiac myocytes (Figure 4B). Nox4-induced increases in TUNEL positive myocytes were significantly attenuated in the presence of Bcl-xL, suggesting that the mitochondrial component of apoptosis may be stimulated by Nox4 (Figure 4C). Overexpression of Nox4 induced release of cytochrome c into the cytosolic fraction (Figure 4D). Taken together, these results show that Nox4 stimulates apoptosis in a cell autonomous fashion, but it does not induce hypertrophy at the single myocyte level. Thus the enlargement of cardiac myocytes seen in Tg-Nox4 mice after aging may be a compensatory response of the heart against LV dysfunction.

**Nox4 Is Primarily Localized in Mitochondria**

To elucidate the mechanism by which Nox4 stimulates cardiac dysfunction and increases in cell death during aging, we evaluated the intracellular localization of Nox4 in cardiac myocytes. Immunostaining of cardiac myocytes with the monoclonal antibody (3D2) and confocal microscopic analyses showed that endogenous Nox4 is localized in the perinuclear region, and colocalized with F1F0 ATP synthase in oxidative phosphorylation Complex V, a marker of mitochondria (Figure 5A). When endogenous Nox4 was downregulated by transduction of adenovirus harboring short hairpin (sh)RNA-Nox4, the perinuclear staining with the anti-Nox4 antibody was markedly attenuated (Figure 5A). Staining of overexpressed HA-Nox4
with anti-Nox4 antibody and with anti-HA antibody exhibited identical perinuclear staining patterns (Online Figure V, A and B). These results are consistent with the notion that Nox4 is localized in perinuclear organelles, including mitochondria. Interestingly, staining of p22phox showed an almost identical staining pattern to that of Nox4 (Figure 5B), suggesting that Nox4 is a major partner of p22phox in cardiac myocytes.

Proteins localized in mitochondria have a mitochondrial localization signal (MLS) in their N terminus. An amino acid sequence consistent with the MLS is found in the N-terminal region of Nox4. To further confirm the localization of Nox4, we made an N-terminally deleted Nox4 mutant (Nox4 ΔN: residues 75 to 578) and tested its localization. We found that Nox4 ΔN was no longer localized in the perinuclear region (Figure 5C), on the other hand, an N-terminal fragment of Nox4(1–74) tagged with GFP in its N-terminal region, but not GFP alone, was localized in the perinuclear region, as evidenced by colocalizing with Mitotracker (Figure 5D). All these findings support the notion that Nox4 is primarily localized in mitochondria.

**Nox4 Enhances $O_2^{−}$ Production in Mitochondria**

To obtain biochemical evidence of Nox4 in mitochondria, we prepared mitochondrial fractions from 12-month-old NTg and Tg-Nox4 mouse hearts and examined them for protein expression of Nox4 and $O_2^{−}$ production. The purity of the mitochondrial fraction was confirmed by the absence of BiP, a marker of endoplasmic reticulum, and histone H3, a marker of the nuclear fraction (Figure 6A). Immunoblot analyses showed that Nox4 is present in the mitochondrial fraction, although a lesser amount was also found in the microsomal fraction (Figure 6A). In contrast, expression of endogenous Nox2 was observed primarily in the microsome fraction presumably at the plasma membrane and the level of Nox2 was not increased in Tg-Nox4 (Figure 6A). The lucigenin chemiluminescent assay for $O_2^{−}$ production indicated that NADH-dependent $O_2^{−}$ production was easily detected in the mitochondrial fraction obtained from NTg mouse hearts, and it was significantly greater in Tg-Nox4 than in NTg. NADPH-dependent $O_2^{−}$ production was also observed in both Tg-Nox4 and NTg, but at a lower level than the NADH-dependent $O_2^{−}$ production (Figure 6B). The NADH- and NADPH-dependent $O_2^{−}$ production was also observed in the microsomal fraction, although at much lower levels than in the mitochondrial fraction. The NADH-dependent ROS production in the mitochondrial fractions was inhibited by rotenone, an inhibitor of complex I, by $\sim 50\%$, and further inhibited by diphenyleneiodonium, an inhibitor of
NADPH oxidases, by another ~40% (Figure 6C). The fluorescent intensity of MitoSOX, a specific indicator of O$_2^-$ production in the mitochondria, was also enhanced in myocytes overexpressing Nox4 (Figure 6D). Thus, these results suggest that significant levels of Nox-dependent O$_2^-$ producing activity in the heart exist in the mitochondrial fraction. Because NADH-dependent O$_2^-$ production in the mitochondria is partially rotenone-dependent, O$_2^-$ production by Nox4 may increase electron leakage from mitochondrial complex I, thereby further stimulating O$_2^-$ production in mitochondria.

**Upregulation of Nox4 Induces Mitochondrial Damage in the Heart**

To evaluate whether increased production of O$_2^-$ by Nox4 leads to mitochondrial dysfunction, the effect of Nox4 on mitochondrial membrane potential was evaluated with TMRE and JC-1 staining in cardiac myocytes. Nox4 induced depolarization of the mitochondrial membrane potential (Figure 7A), suggesting that mitochondrial function/integrity was attenuated in the presence of increased expression of Nox4. To evaluate whether apoptotic cell death induced by Nox4 overexpression is mediated through increased O$_2^-$ in mitochondria, we expressed MnSOD, which is localized in mitochondria and dismutates O$_2^-$, in cardiac myocytes. MnSOD significantly attenuated Nox4-induced increases in O$_2^-$, as evaluated by DHE staining, in cardiac myocytes (Figure 7B), and suppressed Nox4-induced increases in apoptosis, as evaluated by TUNEL assays (Figure 7C), suggesting that mitochondrial O$_2^-$ plays an essential role in mediating apoptosis in the presence of Nox4 overexpression in cardiac myocytes.

We further investigated how increased expression of Nox4 leads to the impairment of mitochondrial function. Increased O$_2^-$ production in the mitochondria may result in greater oxidation of mitochondrial proteins in Tg-Nox4 than in NTg. We tested this hypothesis using a proteomic
The results of ICAT analysis demonstrated that the cysteine residues of many mitochondrial proteins are oxidized in Tg-Nox4 to a greater extent than in NTg. In particular, proteins involved in the TCA cycle, including aconitase-2 and citrate synthase, and the electron transport chain, including components of the NADH dehydrogenase complex, were significantly oxidized at cysteine residues (Figure 8A; Online Figure VI). In addition, components of the mitochondrial permeability transition pore (MPTP) complex, including adenine nucleotide translocase type 1 (ANT1), were highly oxidized in Tg-Nox4 mouse hearts. Consistent with previous reports that oxidation attenuates the function of mitochondrial proteins,19 aconitase-2 and citrate synthase activities were significantly lower in Tg-Nox4 than in NTg (Figure 8B). We confirmed that mitochondrial proteins, including aconitase-2 and ANT1, are similarly oxidized by either increased expression of Nox4 or clinically relevant stimuli such as TAC, as evaluated by iodoacetamide-biotin labeling experiments (Figure 8C).

We also evaluated mitochondrial biogenesis as another mechanism through which Nox4 promotes mitochondrial dysfunction. Expression of genes involved in mitochondrial biogenesis in the heart, including PGC-1α and TFAM, was downregulated, and the mtDNA content was reduced in Tg-Nox4 compared to NTg (Figure 8D). Taken together, these results suggest that increased \( \text{O}_2^- \) production in the mitochondria caused by Nox4 upregulation induces oxidative mitochondrial damage, including oxidation of mitochondrial proteins, thereby leading to mitochondrial dysfunction and apoptotic cell death.

**Discussion**

Using a newly generated anti-Nox4 antibody and cardiac specific Nox4 Tg mice, we here demonstrate three major properties of Nox4 in the heart. First, Nox4 is upregulated on aging and hypertrophic stimulation, including pressure overload. Second, overexpression of Nox4 in the heart increases \( \text{O}_2^- \) production and induces cardiac dysfunction accompanied by increased fibrosis and apoptosis, but not obvious cardiac hypertrophy at the organ level. Third, Nox4 is localized primarily at mitochondria and oxidizes mitochondrial proteins involved in the TCA cycle and the electron transport chain, thereby leading to mitochondrial dysfunction.

The \( \text{O}_2^- \)-producing activity of Nox4 is believed to be determined primarily at the level of protein expression.9 Our results, therefore, suggest that \( \text{O}_2^- \) production by Nox4 should be enhanced in cardiac myocytes subjected to hypertrophic stimuli and aging, which may contribute to increases in oxidative stress in hypertrophied hearts. Oxidative stress at middle age, as evaluated by DHE and 8-OHdG staining, was attenuated in Tg-Nox4-P437H hearts. These results suggest that Nox4 plays an important role in the pathogenesis of heart disease.

---

**Figure 5. Subcellular localization of Nox4 in cardiac myocytes.** A, Cultured cardiac myocytes were transduced with adenovirus harboring shRNA-scramble or shRNA-Nox4. Myocytes were costained with anti-Nox4 antibody and anti-F0F1 ATP synthase antibody, a marker of mitochondria. Merged images are shown on the right. B, Cultured cardiac myocytes were costained with anti-Nox4 and anti-p22phox antibodies. A merged image is shown on the right. C, Cultured cardiac myocytes were transduced with an expression plasmid harboring full length (FL) Nox4-HA or Nox4 lacking MLS [LN(75-578)]-HA. Forty-eight hours after transfection, cells were stained with anti-HA antibody and DAPI. Truncation of the N-terminal region (amino acids 1 to 74) causes disappearance of the perinuclear staining of Nox4 in cardiac myocytes. D, Cardiac myocytes were transduced with expression plasmids harboring either GFP alone or Nox4(1–74)-GFP. Representative images of GFP, Mitotracker and merged images are shown.
role in mediating increases in $\text{O}_2^-$ and oxidative stress attributable to hypertrophic stimulation or aging in the heart. The molecular mechanism which mediates upregulation of Nox4 in response to hypertrophic stimuli remains to be elucidated.

An important question is whether upregulation of Nox4 stimulates cardiac hypertrophy. Overexpression of Nox4 in Tg mice did not induce cardiac hypertrophy at baseline at young ages. On the other hand, although middle-aged Tg-Nox4 mice did not exhibit hypertrophy compared to NTg at the organ level, their myocyte size was greater than that of NTg. However, because cardiac function was attenuated in the middle-aged Tg-Nox4 hearts, the increase in cardiac myocyte size could be caused secondarily by reduced LV function. The lack of cardiac hypertrophy at the organ level despite the presence of hypertrophy at the cell level may be attributable to myocyte loss. This notion is supported by the results of in vitro experiments, in which overexpression of Nox4 induces apoptosis, but not hypertrophy, in myocytes. Alternatively, Nox4 may not only stimulate apoptosis but also either gradually induce hypertrophy or enhance aging-induced hypertrophy in vivo. For example, if myocytes with Nox4 upregulation express antioxidants or cell survival factors sufficient for preventing apoptosis, such cells may eventually undergo hypertrophy. Nox4 induces hypertrophy in the kidney and mesangial cells, and proliferation in pulmonary vascular smooth muscle cells. Thus, the effect of Nox4 on cell growth appears to be cell type-dependent.

Overexpression of Nox4 in Tg-Nox4 hearts significantly increased apoptosis in an age-dependent manner, which was accompanied by increased fibrosis and reduced LV function. Because overexpression of Nox4 significantly increased apoptosis in cultured cardiac myocytes, Nox4 must have cell-autonomous proapoptotic effects. Nox4 also induces differentiation of cardiac fibroblasts into myofibroblasts, thereby stimulating cardiac fibrosis. Enhanced expression of Nox4 attributable to aging increases apoptosis and fibrosis, which may contribute to the age-dependent decline in cardiac function. The reason why cardiac function is normal at baseline in young Tg-Nox4 hearts remains to be elucidated. One possibility is that some other factors are necessary for Nox4 to exert its adverse effects on the heart. Although Nox4 is believed to produce $\text{O}_2^-$ without cytosolic cofactors, the activity of Nox4 may be regulated by cofactors. Insulin induces Nox4 ROS generation within 5 minutes, a response which might be too fast to involve upregulation of Nox4, and Rac1 is required...
for Nox4 activation in mesangial cells.25 Another possibility is that factors suppressing Nox4-derived ROS may be decreased or inactivated with aging.26,27 Our results suggest that catalase is upregulated in young Tg-Nox4 compared to NTg mice. Thus, the heart at young ages may have an ability to adapt to the increased Nox4 expression. Alternatively, the slowly progressive phenotype in the Tg-Nox4 heart could be secondary to other unknown functions of Nox4.

We expect that Nox4-P437H, which cannot use NADPH or NADH, forms a heterodimer with p22phox and disrupts interaction between Nox4 and p22phox, thereby inhibiting O$_2$•− production by endogenous Nox4.28 In theory, Nox4-P437H could inhibit O$_2$•− production by Nox2, another Nox isoform in cardiac myocytes, because Nox2 also forms a heterodimer with p22phox. We believe, however, that the effect of Nox4-P437H is primarily mediated through Nox4 because both endogenous Nox4 and Nox4-P437H are primarily localized in intracellular membranes, whereas Nox2 is localized in the plasma membrane.

Nox4 is localized at focal adhesions in vascular smooth muscle cells,29 in the nucleus in vascular endothelial cells,30 in the endoplasmic reticulum in human endothelial cells,28 and in mitochondria in mesangial cells.31 The diverse subcellular localization of Nox4 in previous reports could be attributable to differences in cell types and/or in the specificity of Nox4 antibodies. Our results, obtained with the newly generated anti-Nox4 specific antibody, suggest that Nox4 is localized in the peri-nuclear region, including in mitochondria, in cardiac myocytes. Immunoblots and biochemical analyses of subcellular fractions from mouse hearts (Figure 6), as well as the presence of the functional MLS (Figure 5C and 5D), support the notion that Nox4 is localized primarily in the mitochondria and partially in the microsomes in cardiac myocytes.

Overexpression of Nox4 enhances O$_2$•− production in mitochondria at both the cellular and tissue levels (Figure 6), suggesting that a similar degree of Nox4 upregulation in response to hypertrophic stimuli (Figure 1C) could increase O$_2$•− production in mitochondria. O$_2$•− produced by Nox4 is rapidly dismutated to H$_2$O$_2$, which is freely diffusible in cells. Thus, in theory, increased production of ROS even outside mitochondria could lead to oxidative damage in mitochondrial proteins. However, increased oxidation of cysteine residues in many mitochondrial proteins in Tg-Nox4 was observed in young mice without obvious cardiac phenotype. Thus, Nox4 localized in the mitochondria could promote oxidation of mitochondrial proteins more efficiently.

In the cardiac mitochondrial fraction of Tg-Nox4, both NADH- and NADPH-dependent O$_2$•− production was sig-
Figure 8. Overexpression of Nox4 causes mitochondrial dysfunction. Purified mitochondrial fractions were prepared from aging Tg-Nox4 and NTg mouse hearts and subjected to ICAT proteomics or biochemical assays. 

A, The ICAT signal at cysteine 385 of aconitase, cysteine 126 of aconitase, cysteine 101 of citrate synthase, cysteine 206 of NADH dehydrogenase (51-kDa subunit), cysteine 367 of NADH dehydrogenase (71-kDa subunit), and cysteine 160 of ANT1 were significantly lower in Tg-Nox4 hearts than in NTg hearts, suggesting that these cysteines are oxidized. 

B, The aconitase activity and the citrate synthase activity in the heart were compared among Tg-Nox4, Tg-Nox4-P437H and NTg mice. 

C, Twelve-month-old NTg and Tg-Nox4 mouse hearts were lysed in the presence of biotinylated iodoacetamide. Biotinylated proteins were pulled down on streptavidin beads and subjected to immunoblotting (left). Three-month-old NTg mice were subjected to TAC or sham operation. The hearts were treated in the same way as above (right). 

D, Evaluation of mitochondrial biogenesis. Twelve-month-old NTg or Tg-Nox4 mouse hearts were subjected to immunoblotting using antibodies raised against PGC-1α and TFAM (left). Quantitative real-time PCR for mitochondrial DNA (right). *P<0.05 vs NTg.
nificantly increased. Interestingly, a greater level of O2− was produced from NADH than from NADPH, consistent with the notion that Nox4 can use NADH efficiently as an electron donor.9,17,23 Importantly, both rotenone, an inhibitor of complex I, and diphenyleneiodonium, an inhibitor of NADPH oxidase, significantly inhibited the NADH-dependent ROS production in the mitochondrial fraction (Figure 6C). Thus, we speculate that Nox4 increases O2− production in mitochondria, which triggers mitochondrial dysfunction, thereby leading to O2− production/leakage from mitochondria (Online Figure VII). Nox4-induced increases in ROS may further stimulate “ROS-induced ROS release,”2,33 where complex I is an important source of ROS,2,32 and oxidation of the MPTP and depolarization of the mitochondrial membrane potential play an important role in enhancing ROS.33

We have shown previously that oxidation of the MPTP complex occurs during pressure overload and is suppressed drastically by overexpression of thioredoxin 1, an antioxidant, in mouse hearts.15 Consistently, critical redox-sensitive cysteine residues of NADH dehydrogenase flavoprotein I, a component of complex I, ANT1, a key component of the MPTP complex, and aconitase-2, an established redox sensitive protein, are highly oxidized in Tg-Nox4. Because cysteine oxidation of these proteins also occurs by pressure overload, upregulation of Nox4 may play an important role in mediating cysteine oxidation of mitochondrial proteins during cardiac stress. Upregulation of Nox4 also negatively regulates mitochondrial biogenesis. Taken together, Nox4 strongly drives oxidative stress in mitochondria in the heart, either alone or by enhancing ROS-induced ROS release, which in turn enhances mitochondrial dysfunction and myocardial cell death, thereby leading to the development of cardiac dysfunction.

Acknowledgments

We thank Daniela Zablocki for critical reading of the manuscript.

Sources of Funding

This work was supported in part by US Public Health Service grants HL 59139, HL67724, HL69020, HL91469, and AG27211 and the Foundation Leducq Transatlantic Network of Excellence.

Disclosures

None.

References


---

**Novelty and Significance**

**What Is Known?**

- The Nox2 and Nox4 isoforms of NAD(P)H oxidase, enzymes producing superoxide from molecular oxygen, are expressed in cardiac myocytes.
- Nox2 mediates increases oxidative stress and cardiac hypertrophy in response to some forms of stress in the heart.

**What New Information Does This Article Contribute?**

- Upregulation of Nox4 in response to hypertrophic stimuli induces cell death and cardiac dysfunction in the heart.
- Nox4 is localized primarily in mitochondria and increases superoxide production in cardiac myocytes.
- Upregulation of Nox4 induces oxidation and dysfunction of mitochondrial proteins.

Essentially nothing is known regarding the isoform-specific function of Nox4 in the heart. We sought to elucidate whether increased expression of Nox4 increases oxidative stress, whether Nox4 affects growth and death of cardiac myocytes, and where Nox4 is localized in cardiac myocytes. Using a newly generated Nox4-specific monoclonal antibody and cardiac specific Nox4 overexpressing mice, we demonstrate that increased expression of Nox4 in the heart induces apoptosis of cardiac myocytes and left ventricular dysfunction. Nox4 is localized primarily in mitochondria and produces superoxide in cardiac myocytes. Upregulation of Nox4 induces oxidation of mitochondrial proteins, which in turn induces mitochondrial dysfunction, including MPTP opening and cytochrome c release. The findings that Nox4 is localized in mitochondria and that increased expression of Nox4 induces mitochondrial dysfunction are particularly important because pathological hypertrophy is accompanied by increases in oxidative stress in mitochondria, mitochondrial dysfunction, and consequent increases in cardiac myocyte apoptosis. Thus, our results suggest that Nox4 may be an important source of oxidative stress in the failing heart. Targeted inhibition or deletion of Nox4 specifically may reduce oxidative stress and cell death, thereby improving heart function in patients with pathological cardiac hypertrophy.
Upregulation of Nox4 by Hypertrophic Stimuli Promotes Apoptosis and Mitochondrial Dysfunction in Cardiac Myocytes
Tetsuro Ago, Junya Kuroda, Jayashree Pain, Cexiong Fu, Hong Li and Junichi Sadoshima

Circ Res. published online February 25, 2010;
Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/early/2010/02/25/CIRCRESAHA.109.213116.citation

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2010/02/25/CIRCRESAHA.109.213116.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org//subscriptions/
Online Data supplement

Primary culture of neonatal rat ventricular myocytes
Primary cultures of ventricular cardiac myocytes were prepared from 1-day-old Crl: (WI) BR-Wistar rats (Harlan). A cardiac myocyte-rich fraction was obtained by centrifugation through a discontinuous Percoll gradient as described 1.

Adenoviruses
Adenovirus vectors harboring HA-tagged Nox4 (Ad-Nox4), Nox2 (Ad-Nox2), a catalytically inactive form of Nox4 (Ad-Nox4-P437H), or shRNA-Nox4 (Ad-shRNA-Nox4) were generated using the AdMax system (Clontech). The recombinant adenoviruses were generated in HEK293 cells by co-transfection with a cosmid (pBHGloxΔE1,3Cre) containing the adenovirus type 5 genome (devoid of E1 and E3) and pDC316, a shuttle vector, containing a gene of interest. An adenovirus vector harboring LacZ (Ad-LacZ) was used as control.

For preparation of shRNA-Nox4, a hairpin-forming pair of oligonucleotides (GACCTGGCCAGTATATTATTTCAAGAGAATAATATACTGGCCAGGTCTTTTTT and AGCTAAAAAAGACCTGGCCAGTATATTATTTCCCTTGAATAATATATGGCCAGGTCGGC) were synthesized, annealed, and subcloned into pDC-silencer (Ambion). A recombinant shRNA-Nox4 adenovirus was also generated in HEK293 cells by co-transfection with pBHGloxΔE1,3Cre and the shuttle vector harboring shRNA-Nox4. Adenovirus harboring Bcl-xL has been described 2.

Assays for apoptosis
TUNEL staining was conducted as described 3, 4. Deparaffinized sections were incubated with proteinase K, and DNA fragments were labeled with fluorescein-conjugated dUTP using TdT (Roche Molecular Biochemicals). Nuclear density was determined by manual counting of DAPI-stained nuclei in six fields of each animal using the 40 x objective. TUNEL-positive nuclei in the entire section were identified and counted using the same power objective. Histone-associated DNA fragments were quantified by the Cell Death ELISA (Roche) according to the manufacturer's instruction 3. The mitochondrial-free cytosolic fraction was prepared as described previously 3.

Echocardiography
Mice were anesthetized using 12 µL/g BW of 2.5% avertin (Sigma-Aldrich), and echocardiography was performed using ultrasonography (Acuson Sequoia C256; Siemens Medical Solutions). A 13-MHz linear ultrasound transducer was used. M-mode measurements of left ventricular (LV) internal diameter were taken from more than three beats and averaged. LV end-diastolic diameter (LVEDD) was measured at the time of the apparent maximal LV diastolic dimension, while LV end-systolic diameter (LVESD) was measured at the time of the most anterior systolic excursion of the posterior wall. LV ejection fraction (LVEF) and percent fractional shortening (%FS) were calculated as follows: LVEF = [(LVEDD)³ – (LVESD)³]/(LVEDD)³; %FS = (LVEDD – LVESD)/LVEDD × 100 5.

Aortic banding
The method to impose pressure overload in mice has been described. Mice were anesthetized with a mixture of ketamine (0.065 mg/g), xylazine (0.013 mg/g), and acepromazine (0.002 mg/g) and mechanically ventilated. The left chest was opened at the second intercostal space. Aortic constriction was performed by ligation of the
transverse thoracic aorta between the innominate artery and left common carotid artery with a 28-gauge needle using a 7-0 braided polyester suture. Sham operation was performed without constricting the aorta. To measure arterial pressure gradients, high-fidelity micronanometer catheters (1.4 French; Millar Instruments Inc., Houston, Texas, USA) were used.

**Continuous infusion of angiotensin II and phenylephrine**
Continuous infusion of hypertrophic agonists or vehicle control was conducted with osmotic mini-pumps (model 2002, Alza Corp., Palo Alto, CA, USA) as described previously. Control mice received pumps filled with 0.9% sodium chloride.

**Immunoblot analyses**
Heart homogenates and cardiac myocyte lysates were prepared in RIPA lysis buffer containing 50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1% IGEPAL CA-630, 0.1% SDS, 0.5% deoxycholic acid, 10 mmol/L Na₄P₂O₇, 5 mmol/L EDTA, 0.1 mmol/L Na₅VO₄, 1 mmol/L NaF, 0.5 mmol/L 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF), 0.5 µg/ml aprotinin, and 0.5 µg/ml leupeptin. Samples were subjected to SDS-PAGE. Proteins were transferred onto polyvinylidene fluoride microporous membranes (Bio Rad) and probed with primary antibodies. These include monoclonal antibodies raised against Nox4 (see above), anti-GAPDH (Sigma), anti-actin (Sigma), anti-cytochrome c (Santa Cruz), and polyclonal antibodies raised against p22-phox (Santa Cruz) and anti-BiP (Cell Signaling Technology).

**Immunostaining**
Neonatal rat cardiac myocytes grown on chamber slides (Lab-Tek®) were washed three times with PBS. The cells were fixed with 4% paraformaldehyde, and washed four times with PBS containing 0.1% Triton X-100. The cells were boiled for 10 min with a pressure-cooker to allow the antigen to be better exposed to the antibody. Then the cells were blocked with PBS containing 5% normal goat serum for 60 min and stained with antibodies as indicated.

**Histological analyses**
The LV accompanied by the septum was cut into base, mid portion, and apex, fixed with 10% formalin, embedded in paraffin, and sectioned at 6 µm thickness. The sections were incubated in 3% H₂O₂ in PBS to prevent endogenous peroxidation and blocked with 5% BSA in PBS. Anti–8-hydroxy-2′-deoxyguanosine (anti–8-OHdG) antibody (Oxis International Inc.) was diluted to 7.5 µg/ml in PBS and applied to the sections for 1 hour at 37°C. After washing, biotinylated secondary antibody (anti-mouse IgG; BD Pharmingen) was applied for 1 hour, followed by streptavidin-HRP (BD Pharmingen) for 30 minutes at room temperature. Myocyte cross-sectional area was measured from images captured from sections stained with anti-wheat germ agglutinin (WGA) antibody as previously described. The outlines of 100–200 myocytes were traced in each section. Interstitial fibrosis was evaluated by Masson Trichrome staining. Confocal microscopic analyses were conducted as described previously.

**Dihydroethidium (DHE) staining**
After harvest, heart tissues were immediately embedded in OCT compound in ethanol-dry ice and stored at -80°C. Unfixed frozen samples were cut into 5 µm-thick sections and placed on glass slides. DHE (10 µmol/L) was applied to each tissue section, and then the sections were coverslipped. The slides were incubated in a light-protected humidified chamber at 37°C for 30 minutes. Ethidium fluorescence (excitation at 490 nm,
emission at 610 nm) was examined by fluorescent microscopy. The level of \( \text{O}_2^\bullet^- \) in the mitochondria was also evaluated with Mitosox\textsuperscript{TM} Red (Invitrogen) according to the manufacturer's instructions.

**Lucigenin assays**

Cytosol, mitochondria and microsome fractions of the heart were suspended in 200 μl of an assay buffer composed of 100 mmol/L potassium phosphate (pH 7.0), 10 μmol/L flavin adenine dinucleotide (FAD), 1 mmol/L NaN\(_3\), and 1 mmol/L EGTA. After preincubation with 5 μmol/L lucigenin, NADH or NADPH was added to a final concentration of 500 μmol/L. The chemiluminescence was continuously monitored using a luminometer. The reaction was terminated by the addition of superoxide dismutase (SOD) (100 μg/ml).

**Evaluation of mitochondrial membrane potential/integrity**

In order to evaluate mitochondrial membrane potential/integrity, staining of cultured cardiac myocytes with tetramethylrhodamine ethyl ester (TMRE) and 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine iodide (JC-1) was conducted using MitoPT\textsuperscript{®} TMRE and MitoPT\textsuperscript{®} JC-1 (ImmunoChemistry Technologies), respectively, according to the manufacturer's instructions.

**Mitochondrial function**

A mitochondrial fraction was prepared from mouse hearts, as previously described. In brief, isolated mouse hearts were homogenized in 10 volumes of ice-cold Buffer A (200 mmol/L mannitol, 50 mmol/L sucrose, 10 mmol/L KCl, 1 mmol/L EDTA, 10 mmol/L Hepes-KOH (pH 7.4), 0.1% bovine serum albumin, and a mixture of protease inhibitors). Homogenates were centrifuged at 600 g for 5 min at 4°C. Supernatants were then centrifuged at 3,500 g for 15 min at 4°C. The pellets were resuspended in Buffer A, and centrifuged at 1,500 g for 5 min. The supernatants were centrifuged at 5,500 g for 10 min at 4°C, and then the pellets were suspended as the mitochondrial fraction in 100 μl of CelLytic M Lysis Reagent (Sigma-Aldrich, St. Louis, MO) for immunoblot analyses or in PBS containing protease inhibitors for lucigenin assays. Lysates containing equal amounts of proteins were assessed for citrate synthase (citrate synthase assay kit, Sigma-Aldrich) and cytochrome \( c \) oxidase (cytochrome \( c \) oxidase assay kit, Sigma-Aldrich) activity.

**Iodoacetamide-biotin labeling experiments**

The heart was freshly removed from each mouse and homogenized in RIPA buffer (50 mmol/L Tris, pH 7.5, 150 mmol/L NaCl, 1% NP-40, 0.1% SDS, 0.5% deoxycholic acid, 10 mmol/L Na\(_4\)P\(_2\)O\(_7\), 5 mmol/L EDTA, 1 mmol/L Na\(_3\)VO\(_4\), 1 mmol/L NaF, and protease inhibitors) containing 200 μmol/L biotinylated polyethyleneoxide iodoacetamide (Sigma). The homogenate was centrifuged at 10,000 x g for 10 min. The supernatant was incubated with streptavidin-beads (Sigma) for 2 hours with rotation at 4 °C. After the beads were washed with RIPA buffer three times, iodoacetamide-labeled proteins were eluted with sample buffer (100 mmol/L Tris, pH 6.8, 2% SDS, 5% glycerol, 2% 2-mercaptoethanol, 0.05% bromophenol blue) by heating at 95 °C for 5 min, separated by SDS-PAGE, and then transferred to Hybond\textsuperscript{TM}-P-polyvinylidene difluoride membranes. Immunoblot analyses were performed using antibodies raised against aconitase-2 and ANT-1 (SantaCruz Biotechnology).

**Quantitative real-time PCR reaction for mitochondrial DNA**

Mitochondrial DNA (mtDNA) content was quantified by real-time PCR of cardiac DNA.
Primer sequences for cytochrome b and β-actin are as follows:
CCACTTCATCTTACCATTATATCGC (forward primer) and
TTTTATCTGCATCTGAGTTTAA (reverse primer) for cytochrome b;
CTGCCTGACGGCCAGG (forward primer) and CTATGGCCTCAGGAGTTTTGTC
(reverse primer) for genomic β-actin.

References


Supplemental Figure I

A) Cardiac myocyte-rich and non-myocyte-rich cultures were treated with phenylephrine (PE, 20 μM) for 48 hours. Cells were harvested and cell lysates were subjected to immunoblotting with specific anti-Nox4 and anti-GAPDH antibodies. B) Immunostaining of the heart tissue from mice at 3 or 12 months of age with the specific anti-Nox4 antibody.

Figure I  Expression of Nox4 in cardiac myocytes. A) Cardiac myocyte-rich and non-myocyte-rich cultures were treated with phenylephrine (PE, 20 μM) for 48 hours. Cells were harvested and cell lysates were subjected to immunoblotting with specific anti-Nox4 and anti-GAPDH antibodies. B) Immunostaining of the heart tissue from mice at 3 or 12 months of age with the specific anti-Nox4 antibody.
Supplemental Figure II

A) Heart homogenates were prepared from Tg-Nox4 (line 13) and Tg-Nox4-P437H and immunoblotted with anti-Nox2 and anti-tubulin antibody. B,C) Basal cardiac phenotype in Tg-Nox4 and Tg-Nox4-P437H mice. LVW/BW (upper) and LVEF (lower) in Tg-Nox4 (lines 3 and 13), Tg-Nox4-P437H (lines 11 and 14), and non-transgenic (NTg) controls at 3-4 months of age. LVEF was evaluated with echocardiographic measurements. Data were obtained from 6-8 mice. The data for NTg mice from all lines were combined. NS, not significant vs. NTg. D) Protein expression of antioxidants and tubulin (internal control) in NTg or Tg-Nox4 mouse hearts was determined with immunoblot analyses. n=3.
Supplemental Figure III

Figure III  Histological findings in Tg-Nox4, Tg-DN-Nox4 and NTg at 13-14 month old.
A) LV myocyte cross sectional area as evaluated by wheat germ agglutinin (WGA) staining. The result of the quantitative analysis is shown. n=5. B) LV fibrosis as determined by Masson’s Trichrome staining. The result of the quantitative analysis is shown. n=5. C) Apoptosis as determined by TUNEL staining. A representative picture from the Tg-Nox4 heart is shown.
Supplemental Figure IV

A) Expression of Nox4 protein was evaluated with immunoblot analyses. n=3.

B) The number of apoptotic cells was evaluated with TUNEL staining. Representative images are shown. n=4-6.

Figure IV  Ad-Nox4 was transduced into cultured neonatal rat cardiac myocytes at various multiplicities of infection (MOI). A) Expression of Nox4 protein was evaluated with immunoblot analyses, n=3. B) The number of apoptotic cells was evaluated with TUNEL staining. Representative images are shown. n=4-6.
Figure V Subcellular localization of Nox4 and DN-Nox4. Cultured ventricular cardiac myocytes were transduced with adenovirus harboring Nox4-HA or DN-Nox4-HA. A) Staining with anti-Nox4 antibody, that with Mitotracker and a merged image are shown. B) Staining with anti-Nox4 antibody, that with anti-HA antibody and a merged image are shown. Note that DN-Nox4-HA showed a staining pattern similar to Nox4-HA.
Supplemental Figure VI

Figure VI Cysteine oxidation of mitochondrial proteins in Tg-Nox4 hearts. Purified mitochondrial fraction was prepared from aging Tg-Nox4 or NTg mouse hearts and subjected to ICAT assays (Inset). Nox4 OE indicates signals from Nox4 overexpressed (Tg-Nox4) hearts. The spectra of MS/MS confirmed the identity of the peptide fragments. Representative ICAT and MS/MS patterns of aconitase (top), citrate synthase (middle) and NADH dehydrogenase flavoprotein 1 (bottom) are shown.
Our hypothesis regarding cardiac function of Nox4.
Aging and hypertrophic stimuli upregulate Nox4 in cardiac myocytes. Upregulation of Nox4 in mitochondria enhances O2- production and oxidation/dysfunction of mitochondrial proteins, such as aconitase and NADH dehydrogenase flavoprotein I, which in trigger leakage of electron from mitochondria and increase oxidative stress. Increases in oxidative stress stimulates ROS-induced ROS release from the mitochondria, thereby promoting mitochondrial dysfunction and further increases in oxidative stress.
Online Table I

<table>
<thead>
<tr>
<th></th>
<th>NTg (n=7)</th>
<th>Tg-Nox4 (n=6)</th>
<th>Tg-Nox4-P437H (n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (month)</td>
<td>13.8 ± 0.7</td>
<td>14.0 ± 0.6</td>
<td>13.8 ± 0.0</td>
</tr>
<tr>
<td>Body Weight (g)</td>
<td>32.3 ± 1.2</td>
<td>30.0 ± 0.7</td>
<td>31.6 ± 1.2</td>
</tr>
<tr>
<td>Heart Rate</td>
<td>450 ± 26</td>
<td>473 ± 38</td>
<td>421 ± 22</td>
</tr>
<tr>
<td>DSEP width (mm)</td>
<td>0.95 ± 0.02</td>
<td><strong>0.87 ± 0.01</strong> <em>ns/</em></td>
<td>1.03 ± 0.05</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>3.71 ± 0.12</td>
<td><strong>3.84 ± 0.05</strong> <em>ns/</em></td>
<td>3.47 ± 0.09</td>
</tr>
<tr>
<td>LVESD (mm)</td>
<td>2.44 ± 0.07</td>
<td>**2.69 ± 0.06 *<strong>/</strong></td>
<td>2.29 ± 0.06</td>
</tr>
<tr>
<td>EF (%)</td>
<td>71.0 ± 0.8</td>
<td>**65.3 ± 1.9 *<strong>/</strong></td>
<td>73.1 ± 1.4</td>
</tr>
</tbody>
</table>

ns not significant, *p < 0.05, **p < 0.01 vs. NTg / Tg-Nox4-P437H

Table I Cardiac dimensions and LV function in Tg-Nox4, Tg-Nox4-P437H and NTg mice at 13-14 months of age, as evaluated by echocardiographic analyses. Hypertrophy and LV dysfunction were observed in Tg-Nox4. DSEP diastolic septal wall thickness, LVEDD left ventricular end diastolic dimension, LVESD left ventricular end systolic dimension, EF ejection fraction.